The active ingredient in Journavx is suzetrigine, a sodium channel blocker. Suzetrigine inhibits the transmission of pain signals to the brain and spinal cord by selectively inhibiting NaV1.8 …
https://www.empr.com/news/journavx-a-nonopioid-oral-pain-medication-gets-fda-approval/

